ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Norcantharidin attenuates amiodarone-induced pulmonary fibrosis via modulating miRNA-30a/GSK-3β/β-catenin and oxidative-inflammatory pathways.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amiodarone-induced pulmonary fibrosis (AIPF) is characterized by inflammation, oxidative stress, microRNA dysregulation, fibroblast activation, and excessive extracellular matrix deposition. Norcantharidin (NCTD), a small-molecule compound with reported anti-inflammatory, antioxidant, and antifibrotic properties, has attracted attention as a potential therapeutic agent. To investigate the protective effects of NCTD against AIPF in rats. Eighteen rats were randomly divided into three groups (n = 6 each): a negative control group receiving vehicle, an amiodarone group, and an NCTD-treated group receiving 0.1 mg/kg intraperitoneally for six weeks. Pulmonary fibrosis was induced by oral administration of 50 mg/kg amiodarone for five weeks. Lung injury was assessed using hematoxylin and eosin staining and semi-quantitative scoring, collagen deposition was evaluated by Masson's trichrome staining, and immunohistochemistry was performed for fibronectin and α-smooth muscle actin (α-SMA). Molecular and biochemical markers including tumor necrosis factor (TNF)-α, β-catenin, interleukin (IL)-1β, malondialdehyde (MDA), and glutathione (GSH) were measured, while glycogen synthase kinase (GSK)-3β was assessed by Western blot, and miRNA-30a by quantitative PCR. Amiodarone significantly increased lung injury scores, collagen deposition, α-SMA, fibronectin, TNF-α, IL-1β, MDA, GSK-3β, and β-catenin, while reducing GSH and miRNA-30a levels. NCTD treatment markedly reversed these alterations, restoring α-SMA, fibronectin, TNF-α, IL-1β, MDA, GSK-3β, and β-catenin, while increasing GSH and miRNA-30a toward normal. Histologically, NCTD preserved alveolar architecture, reduced peribronchiolar inflammation, and normalized collagen distribution. These results demonstrate that NCTD exerts potent antifibrotic, anti-inflammatory, and antioxidant effects in AIPF, likely through modulation of oxidative stress, inflammatory cytokines, microRNA expression, and the GSK-3β/β-catenin signaling pathway, highlighting its potential as a therapeutic agent for drug-induced lung injury.
Indexed as
Identifiers
42525297What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.